The company also announced the receipt of an IDE from the U.S. Food and Drug Administration, to conduct a clinical study examining the combination of Alpha DaRT and first-line chemotherapy in 12 patients with newly diagnosed metastatic pancreatic cancer, as well as the receipt of regulatory approval from France’s Ministry of Health to initiate a French multi-center study examining the use of Alpha DaRT alongside capecitabine in treating locally advanced pancreatic cancer in 40 patients who have responded or had stable disease with first-line FOLFIRINOX.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRTS:
- Alpha Tau to Present Groundbreaking Cancer Therapy Data at ASCO Symposium
- Alpha Tau announces presentation of new data at 2025 ASCO GI Symposium
- Alpha Tau Medical Announces Board Leadership Changes Amid Strategic Expansion
- Alpha Tau Medical Ltd. Announces Key Shareholder Decisions at Annual Meeting
- Alpha Tau appoints Nester to its board of directors